VBL Therapeutics Presents Two Studies on VB-111 at 102nd Annual AACR Meeting
Data highlights promise of novel anti-angiogenic vector as treatment for metastatic cancer and glioblastoma
TEL AVIV, Israel & ORLANDO, Fla.--(BUSINESS WIRE)--Apr 6, 2011 - VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment. The company presented two studies, one demonstrating the safety and specificity of VB-111 and the other demonstrating its promise against glioblastoma, at the American Association for Cancer Research (AACR) 102nd Annual Meeting, taking place this week in Orlando, Fla.
VB-111 is the first targeted, dual-action, anti-angiogenic and Vascular Disruptive Agent (VDA) to use VTS™, the company's proprietary platform technology, for cancer therapy. VB-111 is an IV-administered VDA that works in a manner akin to a “biological knife” to destroy tumor vasculature, thus cutting off the blood vessels feeding the tumor.
“We are pleased to have the opportunity to present these data at AACR among our esteemed colleagues,” said Yael Cohen, M.D., vice president of clinical development at VBL. “These data demonstrate VB-111's promise as a targeted cancer treatment, which is currently being investigated in Phase 2 clinical studies in thyroid cancer and in glioblastoma. VB-111's unique mechanism of action targets tumors with precision and specificity that does not cause any significant damage to the normal non-cancerous tissue or to the normal vasculatures in the body.”
The first study demonstrated that VB-111 was safe and specific and may provide additive effect to chemotherapy. Researchers evaluated the safety and efficacy of VB-111 as monotherapy, in combination with bevacizumab and in combination with carboplatin and pemetrexed in a Lewis Lung metastasis model and found that VB-111 induced a dose-dependent tumor reduction of up to 90 percent.
The second study found that VB-111 has promise as a treatment for glioblastoma. Researchers evaluated the impact of VB-111 on tumor growth in rats with established intracranial xenografts. The results demonstrate decreased tumor size in animals treated with VB-111, with those rats showing a median survival of 48 days, versus 38 days for untreated rats. VBL is currently evaluating VB-111 in a Phase 1/2 trial among patients with glioblastoma.
VB-111 is a dual-action, anti-angiogenic and Vascular Disruptive Agent (VDA) that utilizes VTS™, VBL's proprietary platform technology for cancer therapy. VB-111 is an intravenously administered VDA that works in a manner akin to a “biological knife” to destroy tumor vasculature, thus cutting off the blood vessels feeding the tumor.
Preclinical pharmacological and toxicology studies of VB-111 showed tissue specificity for the tumor tissue, no significant damage to normal non-cancerous tissues or to the normal vasculatures in the body, and a more than 90 percent reduction in metastatic lung cancer model with one injection, as well as similar efficacy in other tumor models. A Phase 1 “all-comers” study of VB-111 in 33 patients with advanced metastatic cancer demonstrated antitumor activity and no effects on liver function or major changes in complete blood count. VB-111 is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma.
About VBL Therapeutics
VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents. VB-201 is the company's lead candidate from this program, currently in Phase 2 clinical development in patients with psoriasis and patients with elevated hsCRP levels. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, a dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma. The company is based in Tel Aviv, Israel. VBL has 70 granted patents and more than 110 patents pending. For more information on the company, please visit www.vblrx.com.
Contact: Pure Communications
Dan Budwick, 973-271-6085
Posted: April 2011